What Zymeworks does

Zymeworks is a Vancouver-headquartered, publicly traded (NASDAQ: ZYME) biotechnology company that has restructured itself as a royalty-driven organization developing antibody-based therapeutics for difficult-to-treat cancers and inflammatory diseases. The company operates a proprietary antibody engineering stack spanning four platforms: Azymetric (heterodimeric bispecific antibody technology clinically validated through the FDA-approved zanidatamab), EFECT (Fc-region effector function modulation), TriTCE (trispecific T cell engagers with conditional CD28 co-stimulation), and ZymeLink ADC payloads (topoisomerase-1 inhibitor, auristatin, and hemiasterlin warheads paired with site-specific conjugation). Its sole commercial product is Ziihera (zanidatamab-hrii), a HER2-directed bispecific antibody approved in the US, EU (conditional), and China for previously treated HER2-positive biliary tract cancer, with a near-term first-line HER2-positive gastroesophageal adenocarcinoma approval decision expected August 25, 2026.

The pipeline includes four clinical-stage assets: ZW191 (FRα-targeting ADC with FDA Fast Track designation for platinum-resistant ovarian cancer, showing 78.6% confirmed ORR in FRα-positive patients in Phase 1), ZW251 (GPC3-targeting ADC for hepatocellular carcinoma), ZW209 (DLL3-targeting trispecific T cell engager for small cell lung cancer), and ZW220 (NaPi2b-targeting ADC). Zymeworks also has ZW1528, an IL-4Rα x IL-33 bispecific for respiratory inflammation/COPD, expanding into non-oncology indications. Partnered assets include pasritamig (CD3 x KLK2 bispecific), which Johnson & Johnson is advancing through Phase 3 for castration-resistant prostate cancer.

Zymeworks generates revenue through tiered royalties (10-20% on Ziihera) and milestone payments (up to $1.36 billion potential from Jazz/BeOne, up to $434 million from J&J) rather than direct commercialization. Three global pharma partners handle manufacturing, regulatory submissions, and sales: Jazz Pharmaceuticals (US/global Ziihera), BeOne Medicines (China/APAC), and Johnson & Johnson (pasritamig globally). The company executed a $250 million non-recourse royalty-backed note financing from Royalty Pharma in March 2026 and authorized a $125 million share repurchase program, holding $403.8 million in cash and equivalents as of Q1 2026 with runway beyond 2028.

Name

Zymeworks

Legal name

Zymeworks BC Inc.

Website

http://zymeworks.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Zymeworks is a Vancouver-based, publicly traded royalty-driven biotechnology company developing antibody-based therapeutics (bispecifics, ADCs, T cell engagers) for difficult-to-treat cancers, with FDA-approved Ziihera for biliary tract cancer and a pipeline of clinical-stage ADC and TCE assets partnered with Jazz, BeOne, and J&J.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Antibody therapeutics
• Bispecific antibodies
• Antibody-drug conjugates
• Oncology drug development
• Biotechnology licensing

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Royalty Revenue from Ziihera: Zymeworks receives tiered worldwide royalties between 10% to 20% on Ziihera (zanidatamab-hrii) sales from Jazz Pharmaceuticals, and tiered royalties up to 19.5% from BeOne Medicines territories. Royalty Pharma holds 30% of Ziihera royalties under the $250M financing deal.
2. Royalty Revenue from Pasritamig: Zymeworks receives tiered worldwide royalties in the mid-single digit percentages from Johnson & Johnson's pasritamig (JNJ-78278343) sales for castration-resistant prostate cancer.
3. Milestone Payments: Zymeworks earns milestone payments upon achievement of regulatory approvals and commercial milestones. Up to $1.36B potential milestone payments from Jazz/BeOne for Ziihera across US, EU, Japan, and China. Additional milestones from J&J partnerships and GSK collaborations. A $250M milestone payment from Jazz is expected upon FDA approval in August 2026.
4. Royalty-Backed Financing: $250M non-recourse royalty-backed note financing from Royalty Pharma, with repayments secured by 30% of worldwide tiered royalties on Ziihera. Royalty Pharma ceases receiving royalties once cumulative payments reach 1.65x the note amount by Dec 31, 2033, or 1.925x at any time thereafter.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Zymeworks is a clinical-stage biopharmaceutical company that designs and develops novel antibody-based therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs), for difficult-to-treat cancers. The company uses proprietary platforms such as Azymetric, EFECT, TriTCE, and topoisomerase-1 inhibitor payload technologies to engineer its pipeline candidates (e.g., Ziihera/zanidatamab, ZW191, ZW251, ZW220, ZW209, ZW1528) and licenses these candidates and platforms to large pharmaceutical partners (Jazz Pharmaceuticals, BeOne Medicines, Johnson & Johnson, GSK) for global development and commercialization in exchange for royalties and milestone payments.

Product overview

Zymeworks is a royalty-driven biotechnology company that has transformed from a clinical-stage biotech into a healthcare asset management organization. The company manages a portfolio of licensed products and develops novel multifunctional biotherapeutics. Its core approved product is Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody for biliary tract cancer. The proprietary pipeline includes multiple antibody-drug conjugates (ZW191, ZW251, ZW220) targeting different tumor antigens using topoisomerase-1 inhibitor payloads, and trispecific T cell engagers (ZW209) and bispecific antibodies (ZW1528) for oncology and inflammatory diseases. These programs are supported by proprietary technology platforms including Azymetric (bispecific antibody engineering), EFECT (effector function modulation), TriTCE (T cell engager with costimulation), and ADC payload technologies. The company generates revenue through royalties and milestone payments from partners including Jazz Pharmaceuticals, BeOne Medicines, and Johnson & Johnson.

Differentiator

Problem solved

Functional benefit

Brands

• Azymetric: Heterodimeric antibody technology platform enabling transformation of monospecific antibodies into multispecific antibodies with alternative target binding formats.
• EFECT
• ZymeLink
• ZW191
• ZW251

Products and services

• Ziihera (zanidatamab-hrii) A bispecific HER2-directed antibody approved by the FDA for treating adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Also in development for gastroesophageal adenocarcinoma and other HER2-expressing cancers.
• ZW191 A folate receptor alpha (FRα)-targeting antibody-drug conjugate using a topoisomerase-1 inhibitor payload (ZD06519) for treatment of advanced solid tumors including ovarian, endometrial, and lung cancers. FDA Fast Track designation granted for platinum-resistant ovarian cancer.
• ZW251 A glypican-3 (GPC3)-targeting ADC using a topoisomerase-1 inhibitor payload for treatment of hepatocellular carcinoma (HCC).
• ZW220 A sodium-dependent phosphate transporter 2b (NaPi2b)-targeting ADC using a topoisomerase-1 inhibitor payload for treatment of ovarian, lung, and pancreatic cancers; IND-ready.
• ZW209 A DLL3-targeting trispecific T cell engager (TriTCE) with conditional CD28 co-stimulation for treatment of small cell lung cancer and other DLL3-expressing cancers.
• ZW1528 An IL-4Rα x IL-33 bispecific antibody designed to address respiratory inflammation including mixed-type COPD by inhibiting multiple cytokine pathways.
• JNJ-78278343 (pasritamig) A CD3 x KLK2 bispecific T cell engager being developed and commercialized by Johnson & Johnson for castration-resistant prostate cancer; eligible for up to $434M in milestones plus tiered worldwide mid-single digit royalties.
• Azymetric Platform A heterodimeric antibody technology enabling engineering of multispecific antibodies that simultaneously bind multiple distinct targets, supporting formats including Fabs, scFvs, and VHHs; available for partnership/licensing.
• EFECT Platform Effector Function Enhancement and Control Technology enabling modification of antibody Fc region to selectively modulate interactions with Fc-gamma receptors and complement (C1q) to enhance or negate immune responses.
• TriTCE Co-Stim Platform Trispecific T cell engager platform with integrated conditional cis CD28 co-stimulation providing T cells with signal 1 (CD3) and signal 2 for enhanced safety and antitumor activity; transferable to diverse targeting strategies.
• Topoisomerase 1 Inhibitor ADC Technology (ZD06519) Camptothecin-based payload specifically designed for ADC use with moderate potency and strong bystander activity, paired with a traceless, plasma-stable, cleavable peptide linker enabling DAR up to 8.

Quantifiable outcome

• 78.6% confirmed objective response rate in FRα-positive platinum-resistant ovarian cancer patients (ZW191 Phase 1)
• +5 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered minor, core/flagship and core.

• GSKminorStrategic or Co-development Partner · 9 June 2020Strategic collaboration for development of bispecific antibodies using Zymeworks' Azymetric platform. Zymeworks eligible for up to $921.8M in potential milestone payments plus tiered worldwide royalties on sales. GSK collaboration achieved $14M milestone in February 2025.
• Jazz Pharmaceuticalscore/flagshipOEM/ Whitelabel/ Licensing Partner · 28 November 2018Licensing agreement for zanidatamab (Ziihera) where Jazz holds US commercialization rights and pays tiered royalties (10-20%) plus milestone payments up to $1.36B. Jazz confirmed opt-in in December 2022 and is pursuing FDA approval for first-line HER2+ gastroesophageal adenocarcinoma with PDUFA date of August 25, 2026.
• BeOne Medicines (BeiGene)core/flagshipOEM/ Whitelabel/ Licensing Partner · 28 November 2018Licensing agreement for zanidatamab where BeOne Medicines holds commercialization rights in China and Asia-Pacific territories, paying tiered royalties up to 19.5% of net sales. BeOne received NMPA approval for HER2-high biliary tract cancer in China and is pursuing additional approvals for gastroesophageal adenocarcinoma.
• Johnson & Johnson (Janssen)coreStrategic or Co-development Partner · 25 October 2017Collaboration for development of bispecific antibodies including pasritamig (JNJ-78278343, CD3 x KLK2) targeting castration-resistant prostate cancer in Phase 3. Zymeworks eligible for up to $434M in milestones and tiered worldwide royalties in mid-single digit percentages. Peak sales opportunity referenced by J&J exceeds $1-5B.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Pyxis Oncology: Pyxis Oncology develops ADCs and immunotherapies for difficult-to-treat cancers, with a focus on novel payload and linker technology. Comparable to Zymeworks' emerging ADC pipeline with similar target patient populations in solid tumors.
• Bolt Biotherapeutics: Bolt Biotherapeutics develops immune-stimulating ADCs (ISACs) combining tumor-targeting antibodies with immune agonists. Shares Zymeworks' focus on novel ADC payloads and difficult-to-treat solid tumor indications.
• Innovent Biologics: Innovent is a Chinese biopharmaceutical company developing bispecific antibodies and ADCs (including IBI354 FRα ADC) for oncology. Comparable to Zymeworks' ZW191 FRα program and partnership with BeOne Medicines for China/APAC commercialization.

Direct peers

• Mersana Therapeutics: Mersana is a clinical-stage ADC company developing novel payloads and linkers for oncology applications. Directly comparable to Zymeworks' ADC platform (ZW191, ZW251, ZW220) and novel topoisomerase-1 inhibitor payload approach.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based therapeutics including toxin conjugates (Bicyclic ADC platform) for oncology, comparable to Zymeworks' ZW191/ZW251 ADC programs. Both companies target solid tumors with novel payload and conjugation approaches.
• MacroGenics: MacroGenics develops bispecific antibodies and antibody-based therapeutics for cancer, sharing Zymeworks' focus on multispecific antibody platforms. Both companies target oncology with proprietary antibody engineering platforms and similar therapeutic indications including solid tumors.
• Genmab: Genmab is a leading bispecific antibody developer (Duobody platform) with multiple approved and clinical-stage products including bispecifics partnered with large pharma. Directly comparable to Zymeworks' Azymetric-based bispecific approach and royalty/partnership business model.

Broad incumbents

• Seagen (Pfizer): Seagen (acquired by Pfizer for $43B) is a leading ADC company with multiple approved products (Adcetris, Padcev, Tukysa, Tivdak) and represents an established incumbent in the ADC space comparable to Zymeworks' ADC pipeline focus.
• ImmunoGen (AbbVie): ImmunoGen (acquired by AbbVie) pioneered ADC technology and markets Elahere, an FRα-targeting ADC for platinum-resistant ovarian cancer. Directly competes with Zymeworks' ZW191 in the same indication with similar target and mechanism.
• Daiichi Sankyo: Daiichi Sankyo developed Enhertu (trastuzumab deruxtecan), the leading HER2 ADC that competes with Ziihera in HER2-positive cancers. Represents a broad incumbent with overlapping HER2 oncology franchise relevant to Zymeworks' partnered bispecific asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zymeworks
• Xx.com/zymeworksinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds16 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zymeworks